MCRB - Seres Nestle Health announce US launch of c. diff therapy Vowst

2023-06-05 14:59:12 ET

Seres Therapeutics ( NASDAQ: MCRB ) and partner Nestle Health Science ( OTCPK:NSRGY ) announced the the US launch of their new treatment Vowst for the prevention of recurrence of C. difficile infection in adults who have already been treated with antibiotics for a recurrence of the illness.

The product, which contains fecal microbiota spores, is intended to prevent recurrence of the infection and is not a treatment for the infection itself, according to the companies.

More on Seres:

Seres receives $125M milestone payment for FDA Approval of Vowst for C. difficile Infection

Seres adds 11% on FDA nod microbiome therapy

For further details see: